오릭 파마슈티컬스(ORIC)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $12.72 (-1.24%), 시가총액 $0.84B, 52주 최저~최고 $5.14 ~ $14.41.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under
오릭 파마슈티컬스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
오릭 파마슈티컬스의 현재 주가는 $12.72 (-1.24%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
오릭 파마슈티컬스의 시가총액은 약 $0.84B입니다.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its